Citigroup Lowers Telix Pharmaceuticals (NASDAQ:TLX) Price Target to $22.00

Telix Pharmaceuticals (NASDAQ:TLX) had its price target reduced by analysts at Citigroup from $22.50 to $22.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 87.15% from the company’s previous close.

Several other research firms also recently commented on TLX. Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Finally, Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Performance

Shares of Telix Pharmaceuticals stock traded down $0.40 during trading hours on Tuesday, reaching $11.76. The company had a trading volume of 75,578 shares, compared to its average volume of 215,724. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $16.98. The business has a fifty day simple moving average of $10.27 and a 200 day simple moving average of $8.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Insider Buying and Selling

In other news, CEO Christian Behrenbruch bought 34,500 shares of the stock in a transaction on Tuesday, April 28th. The stock was acquired at an average cost of $14.48 per share, for a total transaction of $499,560.00. Following the acquisition, the chief executive officer owned 20,709,500 shares of the company’s stock, valued at $299,873,560. This represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TLX. Bank of America Corp DE lifted its stake in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares in the last quarter. Lazard Asset Management LLC boosted its stake in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares in the last quarter. XY Capital Ltd acquired a new stake in shares of Telix Pharmaceuticals in the 1st quarter worth approximately $120,000. Private Advisor Group LLC lifted its holdings in shares of Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares in the last quarter. Finally, Vident Advisory LLC acquired a new position in shares of Telix Pharmaceuticals in the fourth quarter worth $204,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.